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The formation of toxic aggregates composed largely
of the protein a-synuclein are a hallmark of Parkin-
son’s disease. Evidence from both early-onset forms
of the disease in humans and animal models has
shown that the progression of the disease is corre-
lated with the expression levels of a-synuclein, sug-
gesting that cellular mechanisms that degrade
excess a-synuclein are key. We and others have
shown that monoubiquitinated a-synuclein can be
degraded by the 26S proteasome; however, the
contributions of each of the nine known individual
monoubiquitination sites were unknown. Herein, we
determined the consequences of each of the modifi-
cation sites using homogenous, semisynthetic pro-
teins in combination with an in vitro proteasome
turnover assay. The data suggest that the site-spe-
cific effects of monoubiquitination support different
levels of a-synuclein degradation.
INTRODUCTION
The progressive loss of neurons in Parkinson’s disease is closely
associated with the transformation of the protein a-synuclein
from either a helices closely associated with cellular membranes
(Ferreon et al., 2009) or unstructured conformations in solution
(Weinreb et al., 1996) to b sheet-rich, high-molecular weight
aggregates termed Lewy bodies (Fink, 2006). This aggregated
disease state closely resembles the oligomers and fibers that
are readily formed by isolated or recombinant a-synuclein
in vitro. Additionally, when fibers of a-synuclein generated
in vitro were injected into the brains of healthy mice, disease
pathology spread along neuronal contacts and resulted in Par-
kinson’s disease-associated phenotypes, demonstrating that
a-synuclein aggregates can cause disease (Luk et al., 2012).
Notably, duplications and triplications of the gene encoding
a-synuclein cause early-onset forms of Parkinson’s disease
(Chartier-Harlin et al., 2004; Singleton et al., 2003), and several
animal models were generated by a-synuclein overexpressionChemistry & Biology 20, 1207–1(Magen and Chesselet, 2010), strongly suggesting that failure
to maintain the appropriate cellular levels of a-synuclein can in-
crease the rate of aggregation and progression of neurodegen-
eration. Therefore, a molecular understanding of the potential
pathways that lead to a-synuclein degradation has a high prob-
ability to uncover targets for Parkinson’s disease therapy.
We and others have demonstrated that a-synuclein can be
degraded by proteasomal, lysosomal, and autophagic pathways
(Paxinou et al., 2001; Rott et al., 2008; 2011; Webb et al., 2003),
and we have shown that the balance between these different
mechanisms is controlled by the posttranslational modification
of a-synuclein by monoubiquitination (Rott et al., 2011). The
vast majority of ubiquitination result from the enzymatic addition
of the small protein (76 residues) ubiquitin, through its C termi-
nus, to the side-chain amine of substrate protein lysine residues,
giving an isopeptide bond (Welchman et al., 2005). a-Synuclein
has been shown to be modified on nine different lysine residues,
using a variety of techniques (Oueslati et al., 2010). Nonaka et al.
(2005) used rabbit reticulocyte lysates to demonstrate that
monomeric a-synuclein can be monoubiquitinated at lysine res-
idues K21, 23, 32, and 34 and preformed fibrils can be modified
at K6, 10, and 12. Anderson et al. (2006) then showed that a-syn-
uclein isolated from patient Lewy bodies wasmonoubiquitinated
at K12, 21, and 23. Despite the significant amounts of monoubi-
quitinated a-synuclein found in Parkinson’s disease patients, an
enzyme capable of its installation was unknown until we and the
Chin laboratory separately demonstrated that the E3 ubiquitin-
ligases seven in absentia homolog-1 and 2 (SIAH1/2) monoubi-
quitinate a-synuclein in vitro and in vivo (Lee et al., 2008; Liani
et al., 2004; Rott et al., 2008). Mass spectrometry analysis indi-
cated that a-synuclein is monoubiquitinated by SIAH at nine
lysines (K6, 10, 12, 21, 23, 32, 34, 43, and 96) as a heterogeneous
mixture (Nonaka et al., 2005; Rott et al., 2008). Notably, SIAH is
present in Lewy bodies, and ubiquitin modifies a-synuclein in the
same lysines that were found to be monoubiquitinated in Lewy
bodies, supporting its role in Parkinson’s disease (Anderson
et al., 2006; Liani et al., 2004; Rott et al., 2008). Because ubiqui-
tination is often dynamic, we used a candidate-based approach
combined with coimmunoprecipitation, to identify USP9X as a
physiologically relevant DUB that removes a-synuclein monou-
biquitination (Rott et al., 2011). Notably, overexpression of
USP9X, resulting in less a-synuclein monoubiquitination, stabi-
lized a-synuclein protein levels in SH-SY5Y cells, suggesting213, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1207
Chemistry & Biology
Monoubiquitinated a-Syunuclein Degradationthat monoubiquitination can result in a-synuclein proteasomal
degradation. This finding challenged the observation that a pro-
tein requires polyubiquitination of at least four ubiquitin mole-
cules to undergo degradation by the proteasome (Hershko and
Ciechanover, 1998). However, Shabek et al. (2012) recently
found that monoubiquitination, at or near the N terminus of small
proteins (<150 amino acids in length), like a-synuclein, is suffi-
cient to promote proteasomal degradation. Notably, using an
expressed protein ligation strategy, they demonstrated that
a-synuclein monoubiquitinated at K12 is degraded; however,
they did not test the remaining eight modification sites. Further-
more, some studies have shown that SIAH overexpression has
no effect on a-synuclein stability (Nagano et al., 2003).
Using a semisynthetic strategy, we previously demonstrated
that monoubiquitination has different effects on a-synuclein
aggregation, depending on the site of modification (Meier et al.,
2012), andwepredicted that thesamewouldbe true forproteaso-
mal degradation. To directly test this prediction, we utilized a
strategy termed disulfide-directed ubiquitination that generates
a disulfide-linked analog of the ubiquitin-lysine isopeptide bond
(Chatterjee et al., 2010; Chen et al., 2010). This analog has been
shown to be functionally equivalent to native ubiquitin and only
requires a cysteine residue on the substrate protein and ubiquitin
functionalized with a C-terminal thiol. Importantly, a-synuclein
contains no native cysteines, making it a particularly attractive
target for this technology. Here, we use this method to semisyn-
thesize individual a-synuclein molecules bearing monoubiquitin
at eachof theninedifferent knownmodification sites.Subsequent
incubation of these proteins or unmodified a-synuclein with puri-
fiedproteasomesdemonstrated thatdifferentmonoubiquitination
sites vary in their ability to support a-synuclein degradation. Spe-
cifically,monoubiquitination sites toward theN terminus ofa-syn-
uclein are always degraded, whereas those further toward the
center of the protein are typically not turned over. This supports
a model in which individual ubiquitin modification sites have
divergent effects on a-synuclein biology. Furthermore, it strongly
suggests that in general monoubiquitination will only result in
small-protein degradation when it is located near their termini.
RESULTS
Synthesis and Characterization of Monoubiquitinated
a-Synuclein Analogs
The semisynthetic route (Figure 1A) begins with recombinant
expression of ubiquitin as a linear genetic fusion to the fused
AvaDnaE intein (Shah et al., 2012). After purification using a
HisTrap column (GE Healthcare), the ubiquitin was thiolyzed
from the intein by incubation with cysteamine, yielding ubiquitin
with a C-terminal aminoethanethiol linker (Figure S1A available
online). The resulting protein was then reacted with 2,20-
dithiobis(5-nitropyridine) (DTNP) to yield the corresponding acti-
vated mixed-disulfide (Figure S1B) (Rabanal et al., 1996). At this
time, wild-type and the nine lysine-to-cysteine mutants (K6C,
K10C, K12C, K21C, K23C, K32C, K34C, K46C, and K96C) of
a-synuclein were expressed heterologously in Escherichia coli
and purified by reverse-phase (RP) high-performance liquid
chromatography (HPLC). To generate the monoubiquitinated
analogs, the ubiquitin mixed-disulfide was incubated with each
K to Cmutant for 1 hr, resulting in approximately complete prod-1208 Chemistry & Biology 20, 1207–1213, October 24, 2013 ª2013 Euct formation. These nine monoubiquitinated analogs were puri-
fied by RP-HPLC and characterized by mass spectrometry
(Figure 1B) and SDS-PAGE analysis (Figure S2A). Because
a-synuclein that is monoubiquitinated on some sites can still
form protein aggregates that may affect proteasomal activity,
we next characterized all ten proteins using dynamic light scat-
tering. This analysis revealed that all proteins had Stokes radii
of between 3 and 6 nm (Figure S2B), consistent with monomeric
structures, with no evidence of larger oligomers or fibrils.
Visualization of Proteasome-Mediated a-Synuclein
Degradation
To determine if the different monoubiquitinated a-synuclein pro-
teins were degraded by the proteasome required a sensitive
assay to measure both a-synuclein abundance and provide an
internal loading control for signal quantitation. Therefore, we
separated either purified 26S proteasome (360 ng), 26S protea-
some (360 ng) with unmodified a-synuclein (150 ng), or 26S
proteasome (360 ng) with monoubiquitinated a-synuclein (K96,
150 ng), using SDS-PAGE. The gel was then subjected to
colloidal silver staining and imaged on a ChemiDoc XRS (Bio-
Rad) (Figure 2). Importantly, both a-synuclein proteins separated
completely from any proteasomal subunits that could therefore
be used as an internal loading control.
Proteasomal Turnover of Site-Specifically
Monoubiquitinated a-Synuclein Proteins
With a functional assay in hand, each of the ten different a-syn-
uclein proteins (150 ng) were incubated in triplicate with purified
26S proteasomes (360 ng) supplemented with ATP and an ATP-
regenerating system (total volume of 15 ml). Reactions were
terminated after different lengths of time (0, 2, and 4 hr) by the
addition of loading buffer. As a control for proteasome activity
the proteasome inhibitor MG132 (100 mM) was added to a reac-
tion that was allowed to progress for 4 hr. The proteins were
separated by SDS-PAGE, stained with colloidal silver, and
imaged as described above (Figures 3 and S4). Amounts of
a-synuclein or the monoubiquitinated derivatives were quanti-
tated and normalized to the amounts of proteasome subunit as
indicated and relative degradation rates were plotted (Figure 3).
As expected, unmodified a-synuclein was not degraded by the
proteasome over the course of the experiment; however, the
monoubiquitinated proteins were turned over in a site-specific
manner. Importantly, modification at K12 resulted in degradation
of a-synuclein, consistent with results from the Ciechanover lab
(Shabek et al., 2012). Other N-terminally located monoubiquiti-
nation sites (K6, K21, and K23) also resulted in high levels of
degradation, between 40 and 59% of a-synuclein after 4 hr. In
contrast, modifications found further into the primary sequence
of a-synuclein (K32, K34, andK96) display no significant turnover
when compared to unmodified a-synuclein. Notably, certain
modification sites (K10 and K43) appear to be distinct from the
other sites and only support a modest (73 to 80% of a-synuclein
remaining after 4 hr) level of degradation.
DISCUSSION
We describe here the comprehensive analysis of the site-
specific effects of monoubiquitination on the proteasomallsevier Ltd All rights reserved
Figure 1. Synthesis and Characterization of Monoubiquitinated a-Synuclein Proteins
(A) Disulfide-directed ubiquitination. Ubiquitin was expressed in E. coli as a fusion with the AvaDnaE intein and thiolyzed with cysteamine to yield ubiquitin with a
C-terminal thiol. This was subsequently activated with DTNP to generate the corresponding ubiquitin mixed-disulfide. This protein was then reacted with
a-synuclein cysteine point mutants to give the corresponding disulfide-directed monoubiquitinated proteins.
(B) Characterization of each a-synuclein protein using RP-HPLC and mass spectrometry.
See also Figures S1 and S2.
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sites of lysine monoubiquitination have divergent consequences
for a-synuclein turnover. Overall, these data support a general
model in which monoubiquitination events that occur toward
the N terminus of a-synuclein (first 25 amino acids) always
result in proteasome-dependent degradation, whereas thoseChemistry & Biology 20, 1207–1located further into the primary sequence, toward the middle
of the protein, typically do not. Most of the monoubiquitination
sites reside in amino acid repeats in the primary sequence,
including those that support degradation and those that do
not. Furthermore, we have previously demonstrated that regard-
less of modification site monoubiquitination does not have a213, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1209
Figure 2. Visualization of a-Synuclein and the Proteasome
Purified proteasome (26S) alone, with unmodified a-synuclein, or with K96
monoubiquitinated a-synuclein was separated by SDS-PAGE and stained with
colloidal silver. Based on molecular weight, the a subunits of the proteasome
were chosen as a loading control.
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a-synuclein (Meier et al., 2012). This argues for relative position
of the monoubiquitin in relationship to the substrate protein pri-
mary-sequence as the most important determinant of proteaso-
mal degradation. Interestingly, modification at K43 supports
some a-synuclein turnover despite being located toward the
middle of the protein, demonstrating that the orientation of
monoubiquitin with respect to a-synuclein may also be an impor-
tant factor. Importantly, we have observed similar effects on the
aggregation of a-synuclein (e.g., K21 monoubiquitination blocks
aggregation, whereas K23 does not) (Meier et al., 2012).
The overall trend we observed (i.e., more efficient turnover of
a-synucleinmonoubiquitinatedat itsN terminus) is veryconsistent
with previous experiments performed by Shabek et al. (2012),
which discovered the phenomenon of monoubiquitin-dependent
degradation of short proteins. Specifically, several of the model
systems described in this paper were generated from N-terminal
genetic fusions of ‘‘lysine-less’’ ubiquitin to substate proteins
and semisynthetic a-synuclein monoubiquitinated at K12. How-
ever, they did not testmodel proteins inwhichmonoubiquitination
was attached in the center of the protein primary sequence. Our
data begin to fill in this experimental limitation and add to the
fundamental understanding of the differences between poly-
and monoubiquitin-mediated protein degradation by strongly
suggesting that monoubiquitin modifications located toward the
center of such a proteinwill not result in significant turnover. Addi-
tionally, this information is key to the complete understanding of
a-synuclein clearance in Parkinson’s disease and for the potential
development of therapies targeted at a-synuclein ubiquitination.
a-Synuclein has been shown to interact with cellular mem-
branes through its N-terminal amphipathic repeat domains
with lysine residues contributing key contacts (Jao et al.,
2008). Therefore, monoubiquitination of specific lysines may
have different effects on these interactions, with implications to
degradation and aggregation. We are currently combining pro-
tein semisynthesis with cell-culture systems to elucidate the
consequences of site-specific monoubiquitination on all three
of these areas, with important therapeutic implications. For
instance, promoting the monoubiquitination of lysine residues
that both block aggregation and promote a-synuclein degrada-
tion should relieve the burden of accumulated a-synuclein and1210 Chemistry & Biology 20, 1207–1213, October 24, 2013 ª2013 Eslow the progression of disease. For example, a-synuclein is
known to be modified by the ubiquitin-like modifier SUMO
(SUMOylation) at K96 and K102 (Dorval and Fraser, 2006; Kim
et al., 2011), suggesting the possibility that SUMOylation at
K96 may change the occupancy of monoubiquitin at other
lysines with corresponding effects on aggregation and turnover.
Thus, studies on any crosstalk between monoubiquitination and
SUMOylation may shed light on molecular pathways that
control a-synuclein degradation and identify enzyme targets
(e.g., deSUMOylating enzymes) for Parkinson’s disease therapy.
SIGNIFICANCE
Parkinson’s disease is the second most common form of
neurodegeneration, caused at least in part by the progres-
sive accumulation and spread of toxic aggregates of the
protein a-synuclein. Therefore, either inhibiting or elimi-
nating this aggregation is an attractive approach toward
the development of therapies that can slow the progression
of disease. Human genetics and animal models have
demonstrated that higher amounts of a-synuclein increase
its aggregation and accelerate the development of Parkin-
son’s disease symptoms, suggesting that strategies to
induce its degradation would be beneficial. To systemati-
cally investigate the consequences of monoubiquitination
on the proteasome-dependent degradation of a-synuclein,
a semisynthetic strategy was employed to generate homog-
enous protein bearing monoubiquitin at each of the nine
known modification sites. Subsequent in vitro turnover ex-
periments revealed that at least six of the monoubiquitina-
tion sites support some degradation of a-synuclein, with
sites located in the N terminus of the protein always result-
ing in degradation. In contrast, monoubiquitination sites
located toward the middle of the protein showed less or no
turnover at all. We believe that these data may explain the
differences previously obtained by using heterogeneous
ubiquitination of a-synuclein by SIAH1/2, and they generate
a biochemical foundation for future investigations of a-syn-
uclein degradation in cellular and animal models of Parkin-
son’s disease. Furthermore, they provide a working model
for the ability of monoubiquitin to support the degradation
of any small protein in a modification-site dependent
manner. Finally, they highlight the key contributions of
chemistry to revealing the consequences of protein post-
translational modifications.
EXPERIMENTAL PROCEDURES
General Methods
The thiol-activating reagent 2,20-dithiobis(5-nitropyridine) (DTNP) was pur-
chased from Sigma-Aldrich, and cysteamine was purchased from Tokyo
Chemical Industry CO. All other commonly used chemical reagents and sol-
vents were obtained from commercial sources (EMD, Novagen, Invitrogen,
Fluka, and Sigma-Aldrich) and used without any further purification. Ultrapure
laboratory-grade water (filtered, deionized, and sterilized) was obtained from
in-houseMilliQ water purification systems. All solutions were prepared in ultra-
pure laboratory water and filter sterilized through a 0.4 mM filter (Genesee
Scientific). Media (Luria-Bertani broth, Miller, Novagen, and Luria-Bertani
broth, Sigma) were prepared, sterilized, and stored in accordance with the
manufacturer’s and standard published protocols. Media were handled in
sterile conditions under an open flame. Stocks of ampicillin (Na salt, EMD) atlsevier Ltd All rights reserved
Figure 3. Proteasome-Dependent Degradation of Monoubiquitinated a-Synuclein
Unmodified or monoubiquitinated a-synuclein proteins were incubated in triplicate with 26S proteasome for the indicated lengths of time. The proteasome
inhibitor MG132 (100 mM) was added as indicated. The proteins were separated by SDS-PAGE, stained with colloidal silver, and quantitated using Quantity One
Analysis Software (Bio-Rad). The turnover of unmodified a-synuclein is shown in each panel for comparison. P, two-tailed t test; error bars represent ± SEM.
See also Figure S3.
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Reverse-phase high-performance liquid chromatography (RP-HPLC) was
performed using an Agilent Technologies 1200 Series HPLC with Diode Array
Detector. Mass spectra were acquired on an API 3000 LC/MS-MS System
(Applied Biosystems/MDS SCIEX). Light scattering data were collected with
a Dynapro Titan temperature controlled microsampler (Wyatt).Chemistry & Biology 20, 1207–1Ubiquitin-Thiol Expression and Purification
E. coli BL21 (DE3) cells transformed with pTXB1-Ub-AvaDnaE plasmid were
grown in 1 l of LB medium containing ampicillin (100 mg/ml) at 37C until
OD600 = 0.6. Then expression was induced by addition of 0.5 mM IPTG and in-
cubation for 16 hr at 18C. Cells were harvested by centrifugation (5,000 3 g,
30 min, 4C). The cell pellets were resuspended by adding 10 ml of lysis buffer213, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1211
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mented with Complete protein inhibitor cocktail. Cells were lysed by sonicat-
ion (35% amplitude, 63 30 s pulses separated by 30 s on ice). The soluble
fraction was recovered by centrifugation (13,000 3 g, 30 min, 4C). The sol-
uble fraction was then loaded on to a 1 ml HisTrap column (GE Healthcare).
After discarding the flowthrough, the column was washed with five column
volumes (CV) of lysis buffer and 10 CV of buffer A (lysis buffer with 50 mM
imidazole). The protein was eluted with buffer B (lysis buffer with 250 mM
imidazole) in 4.5 CV elution fractions. The elution fractions were analyzed
by SDS-PAGE, and the pure fractions containing Ub-AvaDnaEIntein-His
fusion were pooled and dialyzed against buffer C (100 mM sodium phosphate
monobasic, 150 mM NaCl, 1 mM EDTA, and 1 mM TCEP [pH 7.75]). Ubiquitin
was cleaved from AvaDnaE-His fusion by incubating with 100 mM cysteamine
and 50 mM TCEP (in buffer C [pH 7.75]) for 12 hr at 25C. Ubiquitin with C-ter-
minal aminoethane thiol linker was purified by C4 semipreparative RP-HPLC
with a 25%–60% B gradient over 60 min (buffer A: 0.1% TFA in H2O; buffer B:
0.1% TFA, 90% ACN in H2O). Yield of 10.0 mg of Ub-SH/l of culture was
obtained.
Synthesis of Disulfide-Linked Monoubiquitinated a-Synuclein
In a typical reaction 20.0 equivalents of DTNP (7.20 mg, 23.2 mmol) dissolved
in 2.0 ml of a 3:1 (v/v) acetic acid:water mixture was added to Ub-SH
(2.50 mg, 1.2 mmol). The reaction was allowed to proceed for 72 hr at 25C
with stirring. Disulfide-activated ubiquitin was purified by C4 semipreparative
RP-HPLC with a 30%–60% B gradient over 60 min (buffer A: 0.1% TFA in
H2O; buffer B: 0.1% TFA, 90% ACN in H2O). This yielded 6.00 mg (59%) of
the pure Ub-S-nitro-2-pyridinesulfenyl disulfide adduct (Ub-DTNP). Then
1.0 equivalent of a-synuclein cysteine mutant (1.50 mg, 0.065 mmol) and
2.0 equivalents of Ub-DTNP (1.20 mg, 0.136 mmol) were dissolved in 500 ml
of reaction buffer (1 M HEPES, 6 M Gn-HCl [pH 6.93]). The reaction was
allowed to proceed for 1 hr at 25C with continuous shaking. Ubiquitin
conjugated a-synuclein was purified by C4 semipreparative RP-HPLC
with a 30%–60% B gradient over 60 min (buffer A: 0.1% TFA in H2O; buffer
B: 0.1% TFA, 90% ACN in H2O) to yield typically 1.00 mg of a-synuclein
K#-Ub.
Silver Staining
SDS-PAGE was performed using 18% Criterion Tris-HCl polyacrylamide pre-
cast gel. Silver staining of the gels was performed in accordance with the in-
structions provided in the Bio-Rad Silver Stain Plus Kit. Briefly, the resolved
proteins were fixed by incubating the gel in 200ml of fixative enhancer solution
(50% methanol, 20% acetic acid, 10% fixative enhancer concentrate, and
30% deionized distilled water) for 20 min at 25C. Following that, the gel
was rinsed twice with 100 ml of deionized distilled water for 10 min. Gel was
then stained by incubating in 100 ml of staining solution (35 ml of deionized
distilled water, 5 ml of silver complex solution, 5 ml of reduction moderator
solution, 5 ml of image development reagent, and 50ml of development accel-
erator solution) until protein bands became visible (approximately 10–15 min).
Then the staining reaction was stopped by incubating the gel in 100 ml of 5%
(v/v) acetic acid for 15min. Stained gel was then imaged using ChemiDoc XRS
(Bio-Rad).
Proteasome Turnover Assay
Ubiquitin-conjugated a-synuclein K#-Ub or wild-type protein (150 ng) was
incubated at 37C for indicated times with bovine 26S proteasome (360 ng,
Ubiquitin Proteasome Biotechnologies), 40 mM Tris-HCl (pH 7.6), 5 mM
MgCl2, 2 mM ATP, 10 mM creatine phosphate, and 0.1 mg/ml creatine phos-
phokinase at a final volume of 15 ml. When indicated, the proteasome inhibitor
MG132 was added to a final concentration of 100 mM. Reactions were termi-
nated by the addition of 4-fold concentrated sample buffer. Samples were then
boiled, resolved via SDS-PAGE, stained with colloidal silver, and imaged on
ChemiDoc XRS (Bio-Rad).
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